# Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above

> **NCT04886596** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 26675 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** RSVPreF3 OA vaccine

## Key facts

- **NCT ID:** NCT04886596
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-25
- **Primary completion:** 2022-04-11
- **Final completion:** 2024-05-31
- **Target enrollment:** 26675 (ACTUAL)
- **Last updated:** 2025-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04886596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04886596, "Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04886596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*